Clinical trials: RET Driver Mutation
Lung Cancer
Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer
This single-centre prospective study is aimed at analysing, by means of liquid biopsy with next generation sequencing analysis on circulating tumor DNA, resistance mutations arising during therapy with selective inhibitors in…
- Trial name
- MUT-ONC (NCT06081270)
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Milano Bicocca
Non-Small Cell Lung Cancer, RET Driver Mutation
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment…
- Conditions
- Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation
- Trial name
- NCT05800340
- Testing
- Toripalimab, Nab paclitaxel, Pemetrexed
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital